Compare Adaptive Biotechnologies Corp (ADPT) vs Teucrium Corn Fund (CORN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Teucrium Corn Fund — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Teucrium Corn Fund trades at $17.35. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.
| ADPT | CORN | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $22.37 | $19.12 |
52-Week Low | $10.24 | $16.46 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CORN stock trades at $17.45, up 3.5% today, with a bullish technical signal from moving averages and oscillators. Key support is at $17 and resistance at $18. Recent news includes a licensing partnership with Hormel Foods for CORN NUTS® brands (GlobeNewsWire, 2026-05-07).
The outlook is cautiously optimistic given technical momentum, but fundamental data is unavailable. Risks include reliance on brand licensing and broader market volatility. Investors should monitor upcoming earnings for financial health indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →
